Adaptive Biotechnologies ADPT Noncash Lease Expense
Noncash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept adpt:NoncashLeaseExpense.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's noncash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's noncash lease expense?
- Adaptive Biotechnologies (ADPT) reported noncash lease expense of $1.45M in Q1 2026.
- How has Adaptive Biotechnologies's noncash lease expense changed year-over-year?
- Adaptive Biotechnologies's noncash lease expense increased by 10.5% year-over-year, from $1.31M to $1.45M.
- What is the long-term trend for Adaptive Biotechnologies's noncash lease expense?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's noncash lease expense has grown at a -6.5% compound annual growth rate (CAGR), from $7.03M to $5.36M.
- What does noncash lease expense mean?
- This represents the non-cash portion of lease expenses recognized in the operating section of the cash flow statement. It reflects the systematic allocation of lease costs that do not involve an immediate cash outflow, helping to reconcile net income to operating cash flow. Investors use this to distinguish between actual cash lease payments and accounting-based lease expense accruals.